JP2008513354A5 - - Google Patents

Download PDF

Info

Publication number
JP2008513354A5
JP2008513354A5 JP2007522632A JP2007522632A JP2008513354A5 JP 2008513354 A5 JP2008513354 A5 JP 2008513354A5 JP 2007522632 A JP2007522632 A JP 2007522632A JP 2007522632 A JP2007522632 A JP 2007522632A JP 2008513354 A5 JP2008513354 A5 JP 2008513354A5
Authority
JP
Japan
Prior art keywords
composition
antibody
cancer cells
administered
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007522632A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008513354A (ja
Filing date
Publication date
Priority claimed from US10/894,672 external-priority patent/US9249229B2/en
Priority claimed from US10/996,316 external-priority patent/US7408041B2/en
Priority claimed from US11/171,567 external-priority patent/US20060057651A1/en
Application filed filed Critical
Publication of JP2008513354A publication Critical patent/JP2008513354A/ja
Publication of JP2008513354A5 publication Critical patent/JP2008513354A5/ja
Withdrawn legal-status Critical Current

Links

JP2007522632A 2004-07-20 2005-07-19 慢性リンパ性白血病細胞に由来するポリペプチドおよび抗体、ならびにそれらの使用 Withdrawn JP2008513354A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/894,672 US9249229B2 (en) 2000-12-08 2004-07-20 Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US10/996,316 US7408041B2 (en) 2000-12-08 2004-11-23 Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US11/171,567 US20060057651A1 (en) 2000-12-08 2005-06-30 Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
PCT/US2005/025488 WO2006020266A2 (en) 2004-07-20 2005-07-19 Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012053212A Division JP5727406B2 (ja) 2004-07-20 2012-03-09 慢性リンパ性白血病細胞に由来するポリペプチドおよび抗体、ならびにそれらの使用

Publications (2)

Publication Number Publication Date
JP2008513354A JP2008513354A (ja) 2008-05-01
JP2008513354A5 true JP2008513354A5 (enExample) 2008-08-14

Family

ID=35907987

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007522632A Withdrawn JP2008513354A (ja) 2004-07-20 2005-07-19 慢性リンパ性白血病細胞に由来するポリペプチドおよび抗体、ならびにそれらの使用
JP2012053212A Expired - Fee Related JP5727406B2 (ja) 2004-07-20 2012-03-09 慢性リンパ性白血病細胞に由来するポリペプチドおよび抗体、ならびにそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012053212A Expired - Fee Related JP5727406B2 (ja) 2004-07-20 2012-03-09 慢性リンパ性白血病細胞に由来するポリペプチドおよび抗体、ならびにそれらの使用

Country Status (8)

Country Link
US (4) US20060057651A1 (enExample)
EP (2) EP2441777B1 (enExample)
JP (2) JP2008513354A (enExample)
AU (1) AU2005274785B2 (enExample)
CA (1) CA2574488C (enExample)
DK (1) DK2441777T3 (enExample)
ES (1) ES2569240T3 (enExample)
WO (1) WO2006020266A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7408041B2 (en) * 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
WO2008089022A2 (en) * 2007-01-11 2008-07-24 Boehringer Ingelheim International Gmbh Cd200 and its receptor, cd200r, modulate bone mass via the differentiation of osteoclasts
TWI617576B (zh) * 2007-05-21 2018-03-11 艾爾德生物控股有限責任公司 介白素-６（ｉｌ-６）的抗體及其等之用途
US20110014117A1 (en) * 2007-06-28 2011-01-20 Schering Corporation Anti-igf1r
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
AU2016228280B2 (en) * 2007-07-12 2019-02-21 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
EP2178561A1 (en) * 2007-07-25 2010-04-28 Alexion Pharmaceuticals, Inc. Antibodies to cd200 and uses thereof in inhibiting immune responses
WO2009121162A1 (en) * 2008-04-04 2009-10-08 Trillium Therapeutics Inc. Assay for soluble cd200
DE102008023820A1 (de) * 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
US20110311450A1 (en) 2008-12-08 2011-12-22 Zurit Levine Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
US8217149B2 (en) 2008-12-09 2012-07-10 Genentech, Inc. Anti-PD-L1 antibodies, compositions and articles of manufacture
IN2012DN06309A (enExample) * 2010-01-11 2015-09-25 Alexion Pharma Inc
KR20130036192A (ko) * 2010-02-11 2013-04-11 알렉시온 파마슈티칼스, 인코포레이티드 항-ｃｄ200 항체들을 이용한 치료 및 진단 방법
US8999335B2 (en) 2010-09-17 2015-04-07 Compugen Ltd. Compositions and methods for treatment of drug resistant multiple myeloma
CA2826453A1 (en) 2011-02-03 2012-08-09 Alexion Pharmaceuticals, Inc. Use of an anti-cd200 antibody for prolonging the survival of allografts
KR20120093002A (ko) * 2011-02-14 2012-08-22 (주)에이티젠 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트
ES2785349T3 (es) 2011-06-10 2020-10-06 Canada Minister Nat Defence Anticuerpos anti-ricina y sus usos
EP3626739A1 (en) 2011-06-24 2020-03-25 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
WO2013052432A1 (en) 2011-10-05 2013-04-11 Dharmacon, Inc. Optimization of vectors for effective delivery and expression of genetic content
CN103566377A (zh) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
US10548985B2 (en) 2014-01-10 2020-02-04 Birdie Biopharmaceuticals, Inc. Compounds and compositions for treating EGFR expressing tumors
CN105440135A (zh) 2014-09-01 2016-03-30 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
CA2954446A1 (en) 2014-07-09 2016-01-14 Shanghai Birdie Biotech, Inc. Anti-pd-l1 combinations for treating tumors
JP2019505498A (ja) * 2015-12-16 2019-02-28 ザ・ウォルター・アンド・エリザ・ホール・インスティテュート・オブ・メディカル・リサーチ Ｎｋ細胞におけるサイトカイン誘導性ｓｈ２タンパク質の阻害
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
CN115252792A (zh) 2016-01-07 2022-11-01 博笛生物科技有限公司 用于治疗肿瘤的抗-egfr组合
CN115350279A (zh) 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合
WO2017220989A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
US20190048055A1 (en) * 2017-03-31 2019-02-14 Altor Bioscience Corporation Alt-803 in combination with anti-cd38 antibody for cancer therapies
CN108794467A (zh) 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
CN110769827A (zh) 2017-06-23 2020-02-07 博笛生物科技有限公司 药物组合物
WO2019067499A1 (en) 2017-09-27 2019-04-04 Alexion Pharmaceuticals, Inc. BIOMARKER SIGNATURE FOR PREDICTING A TUMOR RESPONSE TO ANTI-CD200 THERAPY
WO2019126133A1 (en) 2017-12-20 2019-06-27 Alexion Pharmaceuticals, Inc. Liquid formulations of anti-cd200 antibodies
WO2019126536A1 (en) 2017-12-20 2019-06-27 Alexion Pharmaceuticals Inc. Humanized anti-cd200 antibodies and uses thereof
CN109239334A (zh) * 2018-09-10 2019-01-18 吉林大学 建立时间分辨荧光免疫层析法检测MxA试剂盒
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN109633142B (zh) * 2018-12-22 2021-08-27 中国人民解放军第四军医大学 一种急性髓细胞性白血病诊断模型的建立方法及其应用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4289747A (en) 1978-12-26 1981-09-15 E-Y Laboratories, Inc. Immunological determination using lectin
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
DE3307869A1 (de) 1983-03-05 1984-09-06 Dragoco Gerberding & Co Gmbh, 3450 Holzminden Methylsubstituierte 1-((3-methylthio)-1-oxo-butyl)-cyclohex-2-ene, verfahren zu deren herstellung und deren verwendung als riech- und aromastoffe
EP0335476A3 (en) 1984-02-08 1989-12-13 Cetus Corporation Recombinant methods for the production of ricin a, ricin b, ricin or diphtheria toxin (dt)a or ab' fragment, suitable hosts and vectors therefor, and conjugates comprising ricin toxin a chain or diphtheria toxin
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
ATE114723T1 (de) 1987-03-02 1994-12-15 Enzon Lab Inc Organismus als träger für ''single chain antibody domain (scad)''.
JPH0246297A (ja) * 1988-08-08 1990-02-15 Takeda Chem Ind Ltd モノクローナル抗体、抗体産生ハイブリドーマおよび抗体の製造法
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5780279A (en) 1990-12-03 1998-07-14 Genentech, Inc. Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
ATE439435T1 (de) 1991-03-01 2009-08-15 Dyax Corp Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon
ES2123001T5 (es) 1991-06-27 2009-04-16 Bristol-Myers Squibb Company Receptor ctl4a, proteinas de fusion que lo contienen y sus usos.
US5728815A (en) 1992-03-30 1998-03-17 Board Of Regents, The University Of Texas System Bone and prostate-derived protein factors affecting prostate cancer growth, differentiation, and metastasis
US5508717A (en) 1992-07-28 1996-04-16 Sony Corporation Computer pointing device with dynamic sensitivity
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
WO1997016221A2 (en) 1995-10-31 1997-05-09 The Uab Research Foundation Genetic induction of receptors for targeted radiotherapy
WO1997021450A1 (en) 1995-12-08 1997-06-19 Brigham And Women's Hospital, Inc. Ox-2 costimulatory molecule
PT892643E (pt) 1996-03-20 2002-09-30 Univ Emory Metodos para inibir uma resposta imunitaria bloqueando os circuitos de gp39/cd40 e ctla4/cd28/b7 e composicoes utilizaveis para o efeito
US6011138A (en) 1997-02-20 2000-01-04 Idec Pharmaceuticals Corporation Gamma-1 anti-human CD23 monoclonal antibodies
US6955811B2 (en) 1997-11-07 2005-10-18 Trillium Therapeutics Inc. Methods of inhibiting immune response suppression by administering antibodies to OX-2
US7223729B2 (en) 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
DE69833779T2 (de) 1997-11-07 2006-11-30 Trillium Therapeutics Inc., Toronto Verfahren und zusammensetzungen zur immunomodulation
DE19829473C2 (de) * 1998-07-01 2000-08-10 Magnus Von Knebel Doeberitz Ch Verfahren zur frühen Diagnose von Carcinomen
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20020192215A1 (en) 1999-04-13 2002-12-19 Schering Corporation, A New Jersey Corporation Novel uses of mammalian OX2 protein and related reagents
US7291330B2 (en) 2000-03-17 2007-11-06 Trillium Therapeutics Inc. MD-1 inhibitors as immune suppressants
US7306801B2 (en) * 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
CA2417874C (en) * 2000-08-03 2012-10-02 Transplantation Technologies Inc. Use of ox-2 inhibitors for the treatment of cancer
US20030017491A1 (en) 2000-09-14 2003-01-23 Zuo-Rong Shi Chromogenic in situ hybridization methods, kits, and compositions
JP2004513660A (ja) 2000-11-22 2004-05-13 トリリウム　セラピューティクス　インコーポレーティッド 切断型ｃｄ２００
MXPA03005036A (es) 2000-12-07 2003-09-05 Lilly Co Eli Proteinas de fusion glp-1.
US20040198661A1 (en) * 2000-12-08 2004-10-07 Bowdish Katherine S. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
AU2004217434B2 (en) * 2000-12-08 2010-08-26 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
WO2002059280A2 (en) * 2000-12-08 2002-08-01 Alexion Pharmaceuticals, Inc. Chronic lymphocytic leukemia cell line and its use for producing an antibody
US7408041B2 (en) * 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US7368535B2 (en) 2001-05-24 2008-05-06 Trillium Therapeutics Inc. CD200 receptors
EP1436404B1 (en) 2001-09-19 2009-11-11 Alexion Pharmaceuticals, Inc. Engineered templates and their use in single primer amplification
WO2003074679A2 (en) 2002-03-01 2003-09-12 Xencor Antibody optimization
AU2003299823A1 (en) 2002-12-27 2004-07-29 Schering Corporation Methods of inducing and maintaining immune tolerance
US20070009957A1 (en) 2003-03-04 2007-01-11 Alexion Pharmaceuticals, Inc. Vectors used to create hybrid constant regions
WO2005007809A2 (en) 2003-05-30 2005-01-27 Alexion Pharmaceuticals, Inc. Antibodies and fusion proteins that include engineered constant regions
US6953417B2 (en) * 2003-11-17 2005-10-11 Borgwarner Inc. Method for controlling a dual clutch transmission
US20050169870A1 (en) 2004-02-02 2005-08-04 Schering Corporation Methods of modulating CD200
WO2005117977A2 (en) 2004-06-02 2005-12-15 Sidney Kimmel Cancer Center Tissue-specific imaging and therapeutic agents targeting proteins expressed on lung endothelial cell surface
CN102746404B (zh) 2004-11-12 2016-01-20 赞科股份有限公司 对FcRn的结合被改变的Fc变体
US20070036786A1 (en) * 2005-07-11 2007-02-15 Nadine Tuaillon Method of treating autoimmune disease using humanized anti-CD16A antibodies
EP1931709B1 (en) * 2005-10-03 2016-12-07 Xencor, Inc. Fc variants with optimized fc receptor binding properties
AU2007207764B2 (en) 2006-01-12 2012-06-07 Alexion Pharmaceuticals, Inc. Antibodies to OX-2/CD200 and uses thereof
US20080131428A1 (en) * 2006-02-24 2008-06-05 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2

Similar Documents

Publication Publication Date Title
JP2008513354A5 (enExample)
CN111630070B (zh) 三特异性蛋白质及使用方法
CN104379602B (zh) 具有条件活性的抗表皮生长因子受体抗体及其使用方法
US9758589B2 (en) Methods for enhancing anti-tumor antibody therapy
KR101017732B1 (ko) 내재화 항-ｃｄ74 항체 및 그 이용방법
JP5214252B2 (ja) ヒト化ｌ２４３抗体
JP6248024B2 (ja) ヒトｏｘ４０受容体に対する結合分子
CN114007699A (zh) 拮抗剂抗cd7抗体
CN109843325A (zh) Cd3结合抗体
Cameron et al. Obinutuzumab: first global approval
Zhang Ofatumumab
KR20160097336A (ko) 신규 항-ｄｐｅｐ3 항체 및 이의 사용 방법
JP2018529635A5 (enExample)
US20130315820A1 (en) Use of an antibody directed against a membrane protein
JP2021167324A (ja) がん治療のための集中インターフェロン免疫療法
US12098201B2 (en) Anti-TIM3 monoclonal antibodies and chimeric antigen receptors
CN106243225A (zh) 新型抗-pd-l1抗体
Gorovits et al. Current Considerations on Characterization of Immune Response to Multi‑Domain Biotherapeutics
JP2019511199A (ja) 新規の抗ｕｐｋ１ｂ抗体及び使用方法
JP2023516195A (ja) Ｃ１９ ｃ３８二特異性抗体
US20240374644A1 (en) Herv-k antibody therapeutics
Daniels et al. An antibody-based multifaceted approach targeting the human transferrin receptor for the treatment of B-cell malignancies
Baliga et al. IGM-2323: High Avidity IgM-based CD20 x CD3 Bispecific Antibody for Enhanced T-Cell Dependent Killing with Minimal Cytokine Release
WO2020018580A1 (en) Bispecific affinity reagent and related methods for pretargeted radioimmunotherapy against cd45+ cell
CN119053340A (zh) 针对pd-l1和cd137的多特异性结合剂与抗pd-1抗体组合用于治疗癌症